EFSF- more news on the path to the retail shelves for the product they believe could be applied transdermally as a potential preventative measure and/or therapy for MRSA Staph.
They announced the company would be going into a laboratory, and using a “Gold Standard” test to determine its efficacy.
Test results will be the first step- assuming a positive result, the path to the store counter would have to be next. However, it strikes me that they would have to show it works in an actual human application somehow, which might be tough. We’ll see how it all pans out. It’s another opportunity in the portfolio of IP that “could” turn into something big.
On to the main topic- the one of concern to the followers of this company- when are they going to generate more robust sales?
Disciples seem to have a very short fuse on this issue these days. Most of the emails of BLOG comments I receive are centered around that issue. Investors tend to be viewing the recent slate of product developments almost as a kind of slight of hand- a distraction if you will to avoid the main issue.
Here’s what I know- the company is moving in the direction of superior distribution for its existing products. They are in CK41′s back pocket nearly daily- putting their best foot forward to get that moving. They are pushing forward on several other fronts that might prove very fruitful.
In the meantime, considering the current microcap market malaise, and the current level of shareholder unhappiness, this issue might be plagued with a bit of tax selling this year.
I’ve had a number of questions about last year’s January gap. Here’s the chart:
I’ve had to expand the chart considerably to show a daily going back that far, but nevertheless you can clearly see the gap.
On Jan 10, ’07 the stock closed at $.18. On Jan 11, the stock opened at $.21, and never came back. Chartists call this a “gap”, and the theory is that all gaps eventually get filled. The whole in the chart acts like a kind of a vacuum to suck the stock back to that level, fill the gap, and start over.
I don’t believe there’s any logic to it. I do believe opportunistic traders will pounce on the stock if it ever does come back and fills that gap.
In the absence of any robust news on sales and/or a return to a healthy microcap environment this year, there is always the chance EFSF could “fill the gap”, at which point it would be a fantastic trading opportunity to go long.
I would guess the chances are worse than 50/50 for this drop for two reasons. 1. If investors wanted to make tax sales on this stock, they have probably done so already, and 2. I believe micros are going to pick up in short order.
Nevertheless, if this stock does fill that gap this year, I would pounce with reckless abandon. 2008 is a new year, with lots of new opportunity for achievement.
I’ve rarely seen a microcap company with so many potential blockbuster opportunities in its pipeline. I’m just asking for one big success.
Comments and questions are welcome.
Alda pharma has just brought to market a similar product to Citroxin. The stock took off yesterday. What would you say the chances of Citroxin being a superior product other than the obvious one of transdermal sucess?
Editor: I have absolutely no way of making a value judgment on that subject. Perhaps EFSF can catch the same interest with some clinical studies.
IF Q #s come out around the 17th or so, what do you think we need to see in order to move the stock north? Also, what are you EXPECTING to see…give us your personal “whisper number” please.
Editor: Sorry- I got to this a little late. I really didn’t have any sort of whisper number in mind. I don’t believe this stock moving is about the quarterly numbers that just came out. I do believe this stock’s upside is all tied to investors believing they will do much bigger numbers down the road. It will take some doing to convince investors real sales will come pouring in.
I had it I sold all my efsf this company is going nowhere look at your chart downward movment snice its high no marketing at all and now that you have a new wed site small cap daily there are no update here. whats up with that
Editor: I’m not sure if there is a question here, but if so, try rephrasing it and I’ll answer it.
Back in Novemeber around the 6th EFSF said they had obtained CPG Consulting of Richmond, Virginia to promote the IMMUNE BAR.
Two CPG names were mentioned, Doreen Swartz and the CFO Kristy Seaton.
I can not find anything on company or employees. I search tirelessly for hours.
Could you please verify, thanking you in advance.
Editor: Not worth the time right now. A lot more on their marketing plans will come out after the 1st of the year, and then we will explore it in much greater detail.
Where is this one going to stop? Seems some investors didn’t like the earnings report.I’m watching my whole portfolio lose value. I don’t know if I should pull the trigger and sell my EFSF and TTGL. I know the whole market is down, but it gets very discouraging losing so much value. Give me some hope that they won’t keep on falling.
Editor: I would say it’s a combination of year end tax selling and a very schizoid market, which means investors are scared to put anymore capital to work. Could be lower levels in store between now and the end of the year, but on very low volume. Next year, everything could change. I think there will be a great January rally in small stocks.
The next time you have communications with EFSF management, would you please tell Ms. Gruden and company that the old adage “silence is golden” doesn’t apply when you’re trying to get a company’s products know. I acknowledge seeing the Cinnergen commercials on TV, but aside from that they have failed to deliver. Where is the Pur-Effect infomercial? Where is the advertisement for the energy bar? Why hasn’t anyone in the medical arena heard of Citroxin’s potential for killing the MRSA infection? If they don’t know how to get their products to market (and they seem to be good products), then they should hire/parter with someone who does.
Editor: I believe you will find they are moving in that direction, but there won’t be much on it this year. January might just bring a refreshing change along those lines.
Creates questions: ” Our cash position remains strong and we anticipate little to no significant research and development expenses in coming quarters.”
Are they firing the R&D folks? How will they get that talent back when they need it, IF they need it—I’m assuming their marketing focus will be successful but that’s never certain. The market not only yawned, it went down with this announcement. Tough situation.
BD
Editor: I don’t believe firing is the right word as they have always outsourced this stuff. I believe they are saying its time to stop developing products, and time to sell them. They are right. Now, they need to execute. I like their portfolio, but they have to monetize the assets. January could bring a refreshing change.
Did you see the report about the USDA being worried about seed potatoes from Canada that were shipped to 8 US states possibly being infected with nematodes? http://ap.google.com/article/ALeqM5g78ykS8_RiAnYQz4GcbzVPHIcQtgD8TFR7900
Why isn’t EFSF jumping on the opportunity to promote Oraphyte?
Editor: I haven’t followed that story, but I don’t believe they should use it to promote their product. They need to focus all their energies on sales right now, not stories. Let’s see what they can get done there.
I guess you get what you pay for In the last press repot they said they are just starting to market there product hope for better results in the near future what was all the BS the last year as you can see share holder no longer want to here the BS you can see it in the price of the stock .20 or maybe were filling in the gap yeh right. don”t tell me to sell I already did
Editor: Thanks for the contribution. I believe your feelings reflect the way a lot of current and former shareholders feel. If you feel that way, selling the stock was the right thing to do.
Why does the information that you present seem “false” or just a guess at time. I’m talking about how you mentioned that there would be some sort of retail deal and diabetes month would show some sort of push? If that lame TV spot where cinnergen was described as just “cinnamon” then that is not enough.
No new retailer, no real push, basically no sales to speak of from RiteAid.. Hey the good news is you can get cinnergen at ebay…2 bottles for 55 bucks free shipping…at least that is a good buy.
Editor: False? Not sure what you mean. I just relay what I hear. Glad you found some good news in all this. If their efforts on the retail side are too weak for you, just sell the stock. That’s the way you vote. I don’t believe I have ever published anything false. This is opinionated content. My opinion on this one is the same as yours- big disappointment on their failed efforts to generate sales. I’m just not quite as negative on the future as many people seem to be, because I like their portfolio and the way they have managed their cash.